- **Rituximab** anti-CD20 : non-Hodgkin's lymphoma
- **Alemtuzumab** anti-CD52 : CML
- **Muromonab** anti-CD3 : 腎移植
- **Daclizumab/Basiliximab** anti-IL-2R : 腎移植
- **Infliximab/Certolizumab/Adalimumab/Golimumab** TNF-$\alpha$ : RA
- **Tocilizumab** anti-IL-6R : RA
- **Canakinumab** anti-IL-1$\beta$ : Muckle-Wells syndrome
- **Denosumab** anti-RANK-L : 骨質疏鬆
- **Ustekinumab** anti-IL-12/23 : 乾癬
- **Natalizumab** anti-$\alpha4$ integrin : MS
- **Omalizumab** anti-IgE : 過敏
- **Belimumab** anti-BLyS : SLE
- **Ipilimumab** anti-CTLA-4 : 轉移性黑色素瘤
- **Raxibacumab** anti-炭疽桿菌PA : 炭疽桿菌感染